X4 Pharmaceuticals has entered into a senior secured term loan facility of up to $150 million with K2 HealthVentures LLC, a move the company says will strengthen its financial flexibility as it advances its lead drug candidate toward a potential commercial launch. The new agreement replaces a prior loan and provides the Boston-based firm with additional capital to support corporate activities and the development of mavorixafor for chronic neutropenia.
The first tranche of $80 million was funded at closing and used to repay all obligations under X4's previous loan and security agreement, including $75 million in principal and related fees. An additional $70 million remains available to X4 upon request, subject to approval by K2 HealthVentures and other conditions. The new facility offers a larger total size, a longer interest-only period, and a 48-month maturity compared to the previous arrangement.
David Kirske, Chief Financial Officer of X4 Pharmaceuticals, stated that the partnership strengthens the company's capital position and provides a financial foundation for advancing mavorixafor toward potential FDA approval. Kirske noted that the new structure offers more favorable terms aligned with the company's strategic priorities. He also highlighted near-term milestones, including the expected completion of enrollment in the Phase 3 4WARD trial by the end of 2026 and topline data in the first half of 2028.
Parag Shah, Founding Managing Director and Chief Executive Officer of K2 HealthVentures, described the financing as part of the firm's strategy to serve as a long-term partner to innovative life sciences companies. Shah expressed pleasure at partnering with X4 as it advances mavorixafor for the potential treatment of rare hematology diseases.
Mavorixafor is an orally available CXCR4 antagonist that is already commercially available in the U.S. as XOLREMDI for its first indication. The U.S. Food and Drug Administration has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia. X4 is currently conducting a global pivotal Phase 3 clinical trial, known as 4WARD, to evaluate the drug in chronic neutropenic disorders.
The company included forward-looking statements in its announcement, noting that actual results may differ from expectations due to various risks. These risks include the potential inability to satisfy conditions for accessing additional tranches under the K2 HealthVentures facility or complying with loan covenants such as minimum cash and revenue requirements. X4 cautioned that extending the interest-only period depends on achieving initial U.S. commercial sales of mavorixafor for chronic neutropenia within the projected timeframe. Additionally, changes in the prime rate could increase interest expense, and enrollment in the 4WARD trial or reporting of topline data may not occur within expected timeframes.
Additional details regarding the loan agreement are set to be included in filings with the U.S. Securities and Exchange Commission.